Bcl-7b Inhibitors
Chemical inhibitors of Bcl-7b can exert their effects through various mechanisms by disrupting specific cellular pathways that are crucial for the protein's function or expression. Alisertib, a known Aurora kinase A inhibitor, can cause mitotic arrest and apoptosis, thereby reducing the levels of Bcl-7b indirectly due to decreased cell proliferation and increased cell death. Similarly, GDC-0941, a PI3K inhibitor, can lead to reduced survival signals and diminished Bcl-7b levels as a consequence of apoptosis. Palbociclib (PD 0332991), which inhibits CDK4/6, causes G1 phase cell cycle arrest, leading to a subsequent decrease in Bcl-7b protein levels due to halted cell division. Furthermore, AZD8055, by inhibiting mTOR kinase, can cause a reduction in protein synthesis and cell proliferation, indirectly lowering Bcl-7b protein levels.
The MEK inhibitors Cobimetinib and Trametinib disrupt the MAPK/ERK pathway, leading to decreased cell proliferation and survival, which can in turn reduce Bcl-7b levels as a result of decreased signaling through this pathway. Dasatinib, an Src family kinase inhibitor, can decrease cell proliferation, differentiation, and survival signals, thereby indirectly reducing Bcl-7b levels. Venetoclax, a Bcl-2 inhibitor, can alter the balance of pro- and anti-apoptotic signals leading to cell death and a potential secondary reduction in Bcl-7b levels. Bortezomib, a proteasome inhibitor, increases cellular stress leading to apoptosis, which may reduce Bcl-7b levels as part of the broader cellular response to protein accumulation. Ibrutinib, targeting Bruton's tyrosine kinase, can impair B cell survival, potentially reducing Bcl-7b levels in B cells. Lastly, Thalidomide and Lenalidomide, by inhibiting the cereblon-DDB1 complex, can disrupt protein homeostasis, potentially leading to reduced levels of Bcl-7b due to altered protein degradation pathways.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MLN8237 | 1028486-01-2 | sc-394162 | 5 mg | $220.00 | ||
Alisertib is an Aurora kinase A inhibitor. Aurora kinase A is involved in the regulation of mitosis. Inhibition of this kinase can lead to mitotic arrest and apoptosis, potentially reducing the levels of Bcl-7b due to decreased cell proliferation and increased cell death. | ||||||
GDC-0941 | 957054-30-7 | sc-364498 sc-364498A | 5 mg 10 mg | $188.00 $199.00 | 2 | |
GDC-0941 is a PI3K inhibitor. PI3K signaling is crucial for cell survival and proliferation. By inhibiting PI3K, GDC-0941 can lead to reduced survival signals, which may result in a decrease in Bcl-7b levels as cells undergo apoptosis. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a CDK4/6 inhibitor. CDK4/6 are critical for cell cycle progression. Inhibition of these kinases can cause cell cycle arrest in G1 phase, which can lead to reduced expression of Bcl-7b as a result of halted cell proliferation. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055 is an mTOR kinase inhibitor. mTOR signaling affects cell growth and survival. Inhibition of mTOR by AZD8055 can cause a reduction in protein synthesis and cell proliferation, which can indirectly lower Bcl-7b protein levels due to a general decrease in cellular metabolism and growth. | ||||||
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
Cobimetinib is a MEK inhibitor. MEK is part of the MAPK/ERK pathway which is involved in cell proliferation and survival. By inhibiting MEK, cobimetinib can reduce ERK-mediated signaling, leading to decreased survival and proliferation, potentially reducing Bcl-7b levels. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a MEK inhibitor similar to cobimetinib, and it also disrupts the MAPK/ERK pathway. This leads to a decrease in cell proliferation and survival, potentially causing a reduction in Bcl-7b levels as cells are unable to progress through the cell cycle. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is an Src family kinase inhibitor. Src kinases are involved in multiple signaling pathways that regulate cell proliferation, differentiation, and survival. Inhibition of Src kinases can thus decrease signaling required for the maintenance of Bcl-7b levels in proliferating cells. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
ABT-199 is a Bcl-2 inhibitor. Although it does not directly inhibit Bcl-7b, by reducing Bcl-2, it can disrupt the balance of pro- and anti-apoptotic signals, leading to cell death and a potential secondary reduction in Bcl-7b levels. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor. It can increase cellular stress and lead to apoptosis, which may reduce Bcl-7b levels as part of the broader cellular response to proteasome inhibition and subsequent protein accumulation. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor. BTK is involved in B cell receptor signaling. Inhibition of BTK can lead to impaired B cell survival, which may reduce Bcl-7b levels in B cells as they undergo apoptosis. | ||||||